Skip to main content

33rd Annual Lab Institute

G2 Intelligence


Date: October 15, 2015

Time: 12:30PM - 1:30PM

Location: Hyatt Regency Washington on Capitol Hill, Washington, DC


  • Antitrust and Other Regulatory Issues Raised by Laboratory Transactions

We are proud to announce that Mintz Levin Members Karen Lovitch and Dionne Lomax will be panelists on the topic, "Antitrust and Other Regulatory Issues Raised by Laboratory Transactions," at the G2 Intelligence 33rd Annual Lab Institute 2015, Washington, DC (October 14 - 16, 2015). Mintz Levin is a proud sponsor.

About the Panel

As laboratories and pathology groups face the shift from volume-based to value-based reimbursement and other market pressures, they are considering a variety of options, such as acquiring other laboratories or practices, merging with other organizations, structuring joint ventures, participating in integrated delivery systems such as ACOs, entering into exclusive service contracts, and establishing other strategic relationships. The Federal Trade Commission (FTC) and other antitrust authorities have indicated they are paying close attention to health care industry transactions to ensure that value-based reimbursement and other reforms don’t impede or restrain competition. This session will discuss the types of transactions laboratories and pathology groups are pursuing as well as the transactions that competitors are pursuing. Laboratories will also gain insight into the FTC’s perspective on exclusive arrangements and how they impact the parties as well as those who are excluded from exclusive deals and integrated networks.

Learning Objectives

Upon completion of this session, participants will be able to:

  • Describe the types of transactions that laboratories are considering in response to market pressures such as the trend toward value-based reimbursement
  • Recognize the potential effects on competition and the reasons the FTC and other antitrust enforcement authorities are concerned about the anticompetitive impact on the market
  • Identify other potential regulatory concerns implicated by laboratory industry transactions, including anti-kickback and self-referral issues


Karen S. Lovitch

Karen S. Lovitch


Karen advises industry clients on regulatory, transactional, operational, and enforcement matters. She has deep experience handling FCA investigations and qui tam litigation for laboratories and diagnostics companies.